Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Cardiology/Vascular Diseases
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Knoll Pharmaceutical
Approval Status: Approved January 1998
Treatment Area: Paroxysmal atrial fibrillation
Rymol (propafenone hydrochloride) has been approved for use in
patients without structural heart disease, for prolongation of the
time to recurrence of paroxysmal atrial fibrillation/flutter and
paroxysmal supraventricular tachycardia associated with disabling
symptoms. The drug has been marketed in the U.S. since 1990 for
patients with life-threatening ventricular arrhythmias.
In a 12-month study, patients' time to recurrence of
paroxysmal atrial fibrillation/flutter, or sudden arrhythmic
attacks, was eight times longer in patients receiving Rythmol
versus patients treated with placebo.
